1. Home
  2. GILD vs BSX Comparison

GILD vs BSX Comparison

Compare GILD & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GILD
  • BSX
  • Stock Information
  • Founded
  • GILD 1987
  • BSX 1979
  • Country
  • GILD United States
  • BSX United States
  • Employees
  • GILD N/A
  • BSX N/A
  • Industry
  • GILD Biotechnology: Biological Products (No Diagnostic Substances)
  • BSX Medical/Dental Instruments
  • Sector
  • GILD Health Care
  • BSX Health Care
  • Exchange
  • GILD Nasdaq
  • BSX Nasdaq
  • Market Cap
  • GILD 110.9B
  • BSX 120.7B
  • IPO Year
  • GILD 1992
  • BSX 1992
  • Fundamental
  • Price
  • GILD $88.46
  • BSX $90.46
  • Analyst Decision
  • GILD Buy
  • BSX Strong Buy
  • Analyst Count
  • GILD 24
  • BSX 23
  • Target Price
  • GILD $93.91
  • BSX $93.73
  • AVG Volume (30 Days)
  • GILD 7.3M
  • BSX 7.3M
  • Earning Date
  • GILD 11-06-2024
  • BSX 10-23-2024
  • Dividend Yield
  • GILD 3.48%
  • BSX N/A
  • EPS Growth
  • GILD N/A
  • BSX 47.19
  • EPS
  • GILD 0.10
  • BSX 1.21
  • Revenue
  • GILD $28,299,000,000.00
  • BSX $15,911,000,000.00
  • Revenue This Year
  • GILD $5.71
  • BSX $17.61
  • Revenue Next Year
  • GILD $0.37
  • BSX $12.32
  • P/E Ratio
  • GILD $911.55
  • BSX $74.83
  • Revenue Growth
  • GILD 3.31
  • BSX 15.66
  • 52 Week Low
  • GILD $62.07
  • BSX $53.93
  • 52 Week High
  • GILD $98.90
  • BSX $91.08
  • Technical
  • Relative Strength Index (RSI)
  • GILD 46.13
  • BSX 68.63
  • Support Level
  • GILD $89.01
  • BSX $86.01
  • Resistance Level
  • GILD $98.90
  • BSX $89.30
  • Average True Range (ATR)
  • GILD 2.11
  • BSX 1.76
  • MACD
  • GILD -0.63
  • BSX 0.27
  • Stochastic Oscillator
  • GILD 8.58
  • BSX 94.06

About GILD Gilead Sciences Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

About BSX Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Share on Social Networks: